October 1995
Caribbean Business;10/26/1995, Vol. 23 Issue 43, p58
Reports on the financial performance of Pfizer Inc. in the third quarter of 1995. Increase in earnings; Net income posted; Favorable exchange rates' addition of sales growth; Strong sales of products such as the antidepressant Zoloft and the heart medication Norvasc.


Related Articles

  • Pfizer Continues to Dominate in Second Quarter. Jarvis, Lisa // Chemical Market Reporter;7/26/2004, Vol. 266 Issue 3, p8 

    Reports on the strong industrial performance of Pfizer Inc. with stable sales and earnings statistics for the second quarter of 2004 despite greater competition for several key drugs. Net income posted by Pfizer for the said period; Major competitors of Pfizer; Strong sales performance of its...

  • PFIZER'S PUZZLE. Simons, John // Fortune;4/17/2006, Vol. 153 Issue 7, p152 

    The article reports on Hank McKinnell, CEO of Pfizer, the world's largest drug manufacturer. Profits for the company were down almost 30% in 2005, and its shares have lost almost 40% of their value since 2001. At the turn of the century, Pfizer expected revenues to decrease by 33% over a two to...

  • Quarterly Reports.  // Contract Pharma;Mar2014, Vol. 16 Issue 2, p135 

    The article offers information related to the financial performances of several pharmaceutical companies as of fourth quarter of 2013 including Pfizer Inc., AstraZeneca PLC, and Sanofi. Topics discussed include primary care and specialty care revenues of Pfizer were $3.4 billion, pharmaceutical...

  • No magic potion among Pfizer's drugs. Harrington, John // Crain's New York Business;04/23/2001, Vol. 17 Issue 17, p46 

    Reports on an increase in the earnings of New York City-based pharmaceutical firm Pfizer Inc. for the first quarter of the year 2001. Factors behind the increase; Percentage of revenue growth achieved by the firm; Business strategies to further increase the firm's earnings.

  • A Dose of Strong Medicine. P., Shankar // njbiz;6/23/2003, Vol. 16 Issue 25, p35 

    Focuses on the financial performance of the pharmaceutical company Pfizer in New York City. Income posted by the company in 2002; Plans of the company for its business; Drugs that face the loss of their patents.

  • Pfizer Offers Solid 3Q Results.  // Chemical Market Reporter;10/22/2001, Vol. 260 Issue 15, p3 

    Reports on the performance of pharmaceutical company Pfizer as of October 22, 2001. Factors contributing to Pfizer's strong performance; Net income of the company in the third quarter of 2001; Percentage of the market held by the Pfizer drug Lipitor.

  • Pfizer Maintains Steady 3Q Growth.  // Chemical Market Reporter;10/21/2002, Vol. 262 Issue 14, p3 

    Reports on the growth in profits of the pharmaceutical company Pfizer Inc. in the third quarter of 2002. Percentage rise in the company's earnings; Percentage rise in sales of the company; Drugs that contributed to higher sales.

  • Pfizer India Ltd.--implementing restructuring programme.  // Chemical Business;Mar1998, Vol. 12 Issue 3, p80 

    Focuses on the financial performance of Pfizer India Ltd., a pharmaceutical company, for the fiscal year that ended March 1997. Sales; Net profits; Earning per share.

  • Pfizer, Inc. SWOT Analysis.  // Pfizer, Inc. - SWOT Analysis;April 2005, p1 

    Presents an overview of New York City-based Pfizer Inc., a global pharmaceutical and consumer products company that discovers, develops, manufactures and markets medicines for humans and animals. Company overview, including revenues generated during the fiscal year ended December 2004, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics